Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088096 | 0.81 | ULK1 (0.34) | — | |
| SCHEMBL28097912 | 0.74 | MAPT (0.41) | — | |
| SCHEMBL21246893 | 0.74 | AURKA (0.38) | CCR4GAALMNACYP2C9TSHR | |
| SCHEMBL19584225 | 0.70 | LMNA (0.39) | LMNACYP2C9TSHRAPEX1SMN1; SMN2 | |
| SCHEMBL29738545 | 0.69 | CYP3A4 (0.41) | CYP2C9GRM2 | |
| SCHEMBL30989366 | 0.69 | TRPA1 (0.34) | CYP2C9SMN1; SMN2 | |
| SCHEMBL24851926 | 0.69 | CYP3A4 (0.41) | CYP2C9GRM2 | |
| SCHEMBL21262511 | 0.69 | KDM4E (0.42) | CCR4LMNASMN1; SMN2 | |
| SCHEMBL5942443 | 0.69 | KCNJ5 (0.36) | RORCCCR4KCNJ5KCNJ3 | |
| SCHEMBL10948586 | 0.67 | NPC1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-14 | — | — | US | disclosed |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571423-B2 | Small molecule modulators of human sting | STING1, IRF3, CGAS | RORC 863/4885CCR4 4076/4885GAA 1176/4885 |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | RORC 863/4885CCR4 4076/4885GAA 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.